Drug package inserts are a crucial foundation for clinical medication practices and serve as the legal basis for guiding rational drug use and ensuring patient safety and efficacy. As rare disease treatments evolve, current package inserts often need to meet the clinical requirements for treating such conditions, frequently resulting in off-label drug use. This consensus is derived from discussions between Guangdong Pharmaceutical Association Hematologic Rare Diseases Group experts. The consensus aims to provide a framework and reference for the clinical application of off-label drug use in treating rare hematologic diseases.
Keywords: evidence based pharmacy; expert consensus; hematological disease; off-label drug use; rare diseases.
Copyright © 2024 Zhao, Zhou, Zheng, Zhang, Feng, Chen, Cai, Chen, He, Su, Cheng, Zeng, Li, Ji, Wu, Feng, Liu, Jin, Liu, Mo, Wu, Wu, Zhang, Zheng, Zheng, Sun, Li and Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association.